J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Treatment of Helicobacter pylori infection.
TL;DR: If compliance is good and a clear treatment paradigm adhered to, almost universal eradication rates can still be achieved, if compliance is not achievable, the problem of antibiotic resistance will continue to beset any combination of drugs used for H. pylori eradication.
Journal ArticleDOI
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
David Kotlyar,David Kotlyar,James D. Lewis,Laurent Beaugerie,Ann Tierney,Colleen M. Brensinger,Javier P. Gisbert,Edward V. Loftus,Laurent Peyrin-Biroulet,Wojciech Blonski,Wojciech Blonski,Manuel Van Domselaar,María Chaparro,Sandipani Sandilya,Meenakshi Bewtra,Florian Beigel,Livia Biancone,Gary R. Lichtenstein +17 more
TL;DR: Compared with studies from referral centers, population-based studies of IBD patients show a lower but significantly increased risk of lymphoma among patients taking thiopurines, and the increased risk does not appear to persist after discontinuation of therapy.
Journal ArticleDOI
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease
Julián Panés,Damián García-Olmo,Gert Van Assche,Jean-Frederic Colombel,Walter Reinisch,Walter Reinisch,Daniel C. Baumgart,Axel Dignass,Maria Nachury,Marc Ferrante,Lili Kazemi-Shirazi,Jean Charles Grimaud,Fernando de la Portilla,Eran Goldin,Marie Paule Richard,Mary Carmen Diez,Ignacio Tagarro,Anne Leselbaum,Silvio Danese,Jean Fred Colombel,Anton Stift,Jörg Tschmelitsch,Karl Mrak,Herbert Tilg,Irmgard Kroberger,André D'Hoore,Danny De Looze,Filip Baert,Paul Pattyn,Philippe Zerbib,Frank Zerbib,Stephanie Viennot,Jean-Louis Dupas,Pierre-Charles Orsoni,Xavier Hébuterne,Amine Rahili,Matthieu Allez,Yves Panis,Max Reinshagen,Roland Scherer,Andreas Sturm,Wolfgang Kruis,Daniel-Simon Duek,Matti Waterman,Adi Lahat-Zok,Oded Zmora,Hagit Tulchinsky,Y. Edden,Antonino Spinelli,Vito Annese,Imerio Angriman,Gabriele Riegler,Francesco Selvaggi,Bas Oldenburg,Lennard Gilissen,Gust Van Montfort,Mark Löwenberg,Adrianus Willem Bemelman,Raúl Almenara,María Dolores Martín Arranz,Mariano García-Arranz,Javier P. Gisbert,Rosana Palasí,Carlos Taxonera Samso,José Manuel Herrera Justiniano,Ricardo Rada,Mª Teresa Butrón,Daniel Carpio López,Antonio López-Sanromán,Joaquín Hinojosa de Val,Amparo Solana,F. Xavier González Argenté,Carlos Pastor,Héctor Guadalajara +73 more
TL;DR: In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex perianal fistulas, Cx601 is found to be safe and effective in closing external openings, compared with placebo, after 1 year.
Journal ArticleDOI
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse
Javier P. Gisbert,Fernando Bermejo,J.L. Pérez-Calle,Carlos Taxonera,Isabel Vera,Adrian G. McNicholl,Alicia Algaba,P. López,Natalia López-Palacios,Marta Calvo,Yago González-Lama,J.A. Carneros,M. Velasco,J. Maté +13 more
TL;DR: Fecal calprotectin and lactoferrin determination may be useful in predicting impending clinical relapse—especially during the following 3 months—in both CD and UC patients.
Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine:
David Kotlyar,James D. Lewis,Laurent Beaugerie,Colleen M. Brensinger,Javier P. Gisbert,Edward V. Loftus,Laurent Peyrin-Biroulet,Wojciech Blonski,Manuel Van Domselaar,Meenakshi Bewtra,Florian Beigel,Livia Biancone,Gary R. Lichtenstein +12 more
TL;DR: In this paper, the relative risk of lymphoma in patients with inflammatory bowel disease (IBD) exposed to thiopurines and compared relative risk values derived from population-based studies with those from referral center based studies.